First Tracks Biotherapeutics Analysts Increase Their Forecasts After Q2 Results

Benzinga Earnings

Aug 13

First Tracks Biotherapeutics Inc (NASDAQ:TRAX) reported a narrower loss for the second quarter on Wednesday.

The company posted quarterly losses of 95 cents per share, versus losses of $1.47 per share in the year-ago period.

“First Tracks continues to execute against a broad development strategy for our potentially best-in-class CD122 antagonist, ANB033, and anticipates treating patients across four indications in 2027. We believe ANB033 is uniquely positioned to deliver differentiated clinical and biological outcomes across multiple immune-mediated diseases,” said Daniel Faga, president and chief executive officer.

First Tracks shares rose 0.1% to $46.16 in pre-market trading

These analysts made changes to their price targets on First Tracks following earnings announcement.

HC Wainwright & Co. analyst Emily Bodnar maintained the stock with a Buy and raised the price target from $44 to $57.
Piper Sandler analyst Yasmeen Rahimi maintained the stock with an Overweight rating and raised the price target from $54 to $95.
Wedbush analyst Martin Fan maintained the stock with an Outperform rating and raised the price target from $60 to $70.

Considering buying TRAX stock? Here’s what analysts think:

Photo via Shutterstock

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/2659415767"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2659415767\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2659415767?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-13 21:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2659415767","market":"hk","top_or_hot":-1,"title":"First Tracks Biotherapeutics Analysts Increase Their Forecasts After Q2 Results","media":"Benzinga Earnings","content":"<html><body><p><strong><a href=\"https://laohu8.com/S/TRAX\">First Tracks Biotherapeutics Inc</a></strong> (NASDAQ:TRAX) reported a narrower loss for the second quarter on Wednesday.</p>\n<p>The company posted quarterly losses of 95 cents per share, versus losses of $1.47 per share in the year-ago period.</p>\n<p>“First Tracks continues to execute against a broad development strategy for our potentially best-in-class CD122 antagonist, ANB033, and anticipates treating patients across four indications in 2027. We believe ANB033 is uniquely positioned to deliver differentiated clinical and biological outcomes across multiple immune-mediated diseases,” said Daniel Faga, president and chief executive officer.</p>\n<p>First Tracks shares rose 0.1% to $46.16 in pre-market trading</p>\n<p>These analysts made changes to their price targets on First Tracks following earnings announcement.</p>\n<ul>\n<li>HC Wainwright &amp; Co. analyst Emily Bodnar maintained the stock with a Buy and raised the price target from $44 to $57.</li>\n<li>Piper Sandler analyst Yasmeen Rahimi maintained the stock with an Overweight rating and raised the price target from $54 to $95.</li>\n<li>Wedbush analyst Martin Fan maintained the stock with an Outperform rating and raised the price target from $60 to $70.</li>\n</ul>\n<p><strong>Considering buying TRAX stock? Here’s what analysts think:</strong></p>\n<figure><img decoding=\"async\" height=\"314\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/08/13090559/image-372-1024x314.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/08/13090559/image-372-1024x314.png 1024w, https://editorial-assets.benzinga.com/wp-content/uploads/2026/08/13090559/image-372-300x92.png 300w, https://editorial-assets.benzinga.com/wp-content/uploads/2026/08/13090559/image-372-768x235.png 768w, https://editorial-assets.benzinga.com/wp-content/uploads/2026/08/13090559/image-372.png 1148w\" width=\"1024\"/></figure>\n<p><em>Photo via Shutterstock</em></p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>First Tracks Biotherapeutics Analysts Increase Their Forecasts After Q2 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFirst Tracks Biotherapeutics Analysts Increase Their Forecasts After Q2 Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga Earnings </p>\n<p class=\"h-time\">2026-08-13 21:07</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p><strong><a href=\"https://laohu8.com/S/TRAX\">First Tracks Biotherapeutics Inc</a></strong> (NASDAQ:TRAX) reported a narrower loss for the second quarter on Wednesday.</p>\n<p>The company posted quarterly losses of 95 cents per share, versus losses of $1.47 per share in the year-ago period.</p>\n<p>“First Tracks continues to execute against a broad development strategy for our potentially best-in-class CD122 antagonist, ANB033, and anticipates treating patients across four indications in 2027. We believe ANB033 is uniquely positioned to deliver differentiated clinical and biological outcomes across multiple immune-mediated diseases,” said Daniel Faga, president and chief executive officer.</p>\n<p>First Tracks shares rose 0.1% to $46.16 in pre-market trading</p>\n<p>These analysts made changes to their price targets on First Tracks following earnings announcement.</p>\n<ul>\n<li>HC Wainwright &amp; Co. analyst Emily Bodnar maintained the stock with a Buy and raised the price target from $44 to $57.</li>\n<li>Piper Sandler analyst Yasmeen Rahimi maintained the stock with an Overweight rating and raised the price target from $54 to $95.</li>\n<li>Wedbush analyst Martin Fan maintained the stock with an Outperform rating and raised the price target from $60 to $70.</li>\n</ul>\n<p><strong>Considering buying TRAX stock? Here’s what analysts think:</strong></p>\n<figure><img decoding=\"async\" height=\"314\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/08/13090559/image-372-1024x314.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/08/13090559/image-372-1024x314.png 1024w, https://editorial-assets.benzinga.com/wp-content/uploads/2026/08/13090559/image-372-300x92.png 300w, https://editorial-assets.benzinga.com/wp-content/uploads/2026/08/13090559/image-372-768x235.png 768w, https://editorial-assets.benzinga.com/wp-content/uploads/2026/08/13090559/image-372.png 1148w\" width=\"1024\"/></figure>\n<p><em>Photo via Shutterstock</em></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.benzinga.com/analyst-stock-ratings/price-target/26/08/61173753/first-tracks-biotherapeutics-analysts-increase-their-forecasts-after-q2-results","article_id":"2659415767","we_media_id":"1052270027","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2659415767","pubTimestamp":1786626443,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Benzinga Earnings","introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"summary":"TRAX reported narrower Q2 loss of 95 cents per share. Analysts raised price targets for the stock, citing potential for ANB033 in immune diseases.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","TRAX":"First Tracks Biotherapeutics Inc"},"translate_title":"First Tracks 生物治疗分析师在第二季度业绩公布后上调预测","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TRAX":1},"content_text":"First Tracks Biotherapeutics Inc (NASDAQ:TRAX) reported a narrower loss for the second quarter on Wednesday.\nThe company posted quarterly losses of 95 cents per share, versus losses of $1.47 per share in the year-ago period.\n“First Tracks continues to execute against a broad development strategy for our potentially best-in-class CD122 antagonist, ANB033, and anticipates treating patients across four indications in 2027. We believe ANB033 is uniquely positioned to deliver differentiated clinical and biological outcomes across multiple immune-mediated diseases,” said Daniel Faga, president and chief executive officer.\nFirst Tracks shares rose 0.1% to $46.16 in pre-market trading\nThese analysts made changes to their price targets on First Tracks following earnings announcement.\n\nHC Wainwright & Co. analyst Emily Bodnar maintained the stock with a Buy and raised the price target from $44 to $57.\nPiper Sandler analyst Yasmeen Rahimi maintained the stock with an Overweight rating and raised the price target from $54 to $95.\nWedbush analyst Martin Fan maintained the stock with an Outperform rating and raised the price target from $60 to $70.\n\nConsidering buying TRAX stock? Here’s what analysts think:\n\nPhoto via Shutterstock","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"express","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}